Curis, Inc. (NASDAQ:CRIS) is scheduled to announce its earnings results before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

Curis (NASDAQ:CRIS) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The business had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $2.08 million. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. The business’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.09) earnings per share. On average, analysts expect Curis to post $-0.4 EPS for the current fiscal year and $-0.4 EPS for the next fiscal year.

Curis, Inc. (NASDAQ CRIS) opened at 1.65 on Wednesday. The stock’s 50 day moving average price is $1.71 and its 200-day moving average price is $1.90. Curis, Inc. has a 12-month low of $1.47 and a 12-month high of $3.72. The stock’s market capitalization is $237.40 million.

WARNING: “Curis, Inc. (CRIS) to Release Quarterly Earnings on Wednesday” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at

An institutional investor recently raised its position in Curis stock. The Manufacturers Life Insurance Company increased its holdings in Curis, Inc. (NASDAQ:CRIS) by 8.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,023 shares of the biotechnology company’s stock after purchasing an additional 8,102 shares during the period. The Manufacturers Life Insurance Company owned 0.07% of Curis worth $190,000 as of its most recent SEC filing. Institutional investors and hedge funds own 44.72% of the company’s stock.

A number of brokerages have recently commented on CRIS. ValuEngine downgraded Curis from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. BidaskClub downgraded Curis from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Finally, Guggenheim began coverage on Curis in a research report on Monday. They issued a “buy” rating and a $7.00 price objective for the company. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Curis has an average rating of “Hold” and a consensus target price of $6.50.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Earnings History for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with's FREE daily email newsletter.